Cardiff Oncology, Inc.
NASDAQ:CRDFBiotechnology
+$0.03 today
- Market cap
- $65.27M
- Beta
- 1.38
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.65
Volume 0.86M
Average 1.05M
CRDF EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Cardiff Oncology, Inc.NASDAQ: CRDF
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$12.12M, compared with -$13.21M a year earlier. Trailing-twelve-month EBITDA was -$43.73M.
Context
- EBITDA amounted to 7579.6% of revenue in FY2025, up 987.1 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$39.19M (+12.8%) for the fiscal year ending Dec 2026, a step up from the +0.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$12.12M-73.4% QoQ
- Last fiscal yearDec 2025
- -$44.95M+0.2% YoY
- LTMMar 2026
- -$43.73M+9.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +8.2% | +35.8% | +27.6 pp |
| 1 year | +0.2% | +12.8% | +12.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (44.95M) USD
- Year-over-year change
- +0.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (44.95M) | +0.2% |
| FY2024 | 2024-12-31 | (45.03M) | -9.7% |
| FY2023 | 2023-12-31 | (41.04M) | -6.7% |
| FY2022 | 2022-12-31 | (38.47M) | -38.2% |
| FY2021 | 2021-12-31 | (27.84M) | — |
EBITDA vs competitors
How CRDF compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.5% is the 4th highest of 9, against a peer median of -0.6%.
- EBITDA amounts to 8329.5% of revenue for CRDF, versus a peer median of 1566.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$33.38M USD | +31.6% | — | 1053.3% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | -$37.68M USD | +23.9% | — | — |
| FY2025 | -€43.65M EUR | +7.0% | — | 1566.1% | |
| LTM Mar 2026 | -$43.73M USD | +9.5% | — | 8329.5% | |
| LTM Mar 2026 | -$61.36M USD | -27.4% | — | 3439.7% | |
| LTM Mar 2026 | -CHF 63.08M CHF | -8.3% | — | — | |
| LTM Mar 2026 | -$74.38M USD | -70.3% | — | — | |
| LTM Mar 2026 | -$75.99M USD | +22.0% | — | — | |
| LTM Mar 2026 | -$84.28M USD | -67.4% | — | — | |
| Peer median (excluding CRDF) | — | -0.6% | — | 1566.1% | |
Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 359K | 386K | 488K | 683K | 593K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 359K | 386K | 488K | 683K | 593K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 17.38M | 27.11M | 32.86M | 36.85M | 35.33M |
| Selling, General & Admin | 11.84M | 13.18M | 13.04M | 12.48M | 14.22M |
| Operating Expenses | 29.21M | 40.29M | 45.9M | 49.33M | 49.55M |
| Depreciation & Amortization | 451K | 236K | 398K | 404K | 904K |
| EBITDA | (27.84M) | (38.47M) | (41.04M) | (45.03M) | (44.95M) |
| EBITDA Margin | -7754.9% | -9965.8% | -8410.5% | -6592.5% | -7579.6% |
| Operating Income | (28.86M) | (39.9M) | (45.41M) | (48.65M) | (48.96M) |
| Operating Margin | -8037.6% | -10337.3% | -9305.7% | -7123.1% | -8256.3% |
| Interest Income | 264K | 1.58M | 4.07M | 3.26M | 3.1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 564K | 1.2M | 3.97M | 3.22M | 3.11M |
| Income Before Tax | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Pre-Tax Margin | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Net Margin | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
| EPS (Basic) | (0.73) | (0.89) | (0.93) | (0.95) | (0.69) |
| EPS (Diluted) | (0.73) | (0.89) | (0.93) | (0.95) | (0.69) |
| Weighted Avg Shares | 39.03M | 43.6M | 44.68M | 47.65M | 66.84M |
| Weighted Avg Shares (Diluted) | 39.03M | 43.6M | 44.68M | 47.65M | 66.84M |
Cardiff Oncology, Inc.
NASDAQ:CRDF
Intrinsic Alpha fair value
Locked
Current Price
$0.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.